RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On August21, 2017, Brian L. Kotzin, M.D., was appointed to serve on the Board of Directors of Rigel Pharmaceuticals,Inc. (“Rigel”), until his successor is elected and has qualified, or sooner in the event of his death, resignation or removal. Dr.Kotzin joins the class of directors whose term expires at the 2018 annual stockholders’ meeting. Dr.Kotzin was also appointed to serve on the Nominating and Corporate Governance Committee and Scientific& Clinical Trial Advisory Committee of Rigel’s Board of Directors.

As a non-employee director of Rigel, Dr.Kotzin will receive a yearly retainer of $45,000, as well as an additional $10,000 for his service on the Nominating and Corporate Governance Committee and $10,000 for his service on the Scientific& Clinical Trial Advisory Committee.

In addition to the cash compensation referenced in the preceding paragraph, Dr.Kotzin will receive stock option grants under Rigel’s 2000 Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”). Option grants under the Directors’ Plan are non-discretionary. Upon the date of his appointment, Dr.Kotzin received an initial grant to purchase 80,000 shares of common stock on the terms and conditions set forth in the Directors’ Plan. In addition, on the day following each annual meeting of stockholders, Dr.Kotzin will automatically receive an annual option to purchase 40,000 shares of common stock, provided that he continues to serve as a non-employee member of the Board of Directors. Rigel has also entered into its standard form of indemnification agreement with Dr.Kotzin.

There are no arrangements or understandings between Dr.Kotzin and any other persons to which he was elected as a director of Rigel. There are no family relationships between Dr.Kotzin and any director, executive officer, or any person nominated or chosen by Rigel to become a director or executive officer. Dr.Kotzin is not a party to any current or proposed transaction with Rigel for which disclosure is required under Item 404(a)of Regulation S-K.


About RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

An ad to help with our costs